Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sup19 CAR-T in Relapsed/Refractory B-ALL/LBL
NCT07539610Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Sup19 CAR-T in B cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma (B-LBL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Dose-Limiting Toxicity at 28 days. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Sup19 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NCT07539610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07539610.